Osteoporosis and the Potential of Cell-Based Therapeutic Strategies.

1. Introduction

Osteoporosis, a skeletal disorder characterized by low bone mass and increased bone fragility, has no clinical manifestations until a fracture occurs. Osteoporosis is normally diagnosed in elderly patients, being increasingly recognized as a major public health concern [ 1 ]. In 2013 22 million women and 5.5 million men in Europe were affected, representing approximately 6% of men and 21% of women aged 50–84 years. These numbers are seriously escalating over time due to population aging [ 2 ].

Bone is an organ in constant remodeling, finely orchestrated by two principal cell types: osteoclasts that degrade the bone matrix (bone resorption) and osteoblasts which synthesize a new bone matrix (bone formation). In osteoporosis, there is an imbalance between bone resorption and bone formation [ 3 ] mainly due to three mechanisms responsible for developing fragile bone tissue: failure to achieve peak bone mass, excessive bone resorption and/or inadequate formation of new bone during remodeling [ 4 ]. The bone mass of an individual in adulthood depends on the peak bone mass reached during the growth period and the subsequent rate of bone loss [ 5 ]. The achieved maximum bone density in adults is crucial since it contributes to bone density to a larger extent than bone loss rate until at least 15 years after menopause [ 6 ]. Therefore, failure to reach a peak of high bone mass in the first three decades of life would contribute significantly to development of osteoporosis [ 7 ]. A healthy skeleton requires constant remodeling of bone tissue. Under normal conditions, there is a balance between bone formation and resorption, which is necessary to maintain the bone mass and its mechanical resistance properties. This balance is achieved by closely regulating the activity of osteoblasts and osteoclasts, responsible for bone formation and resorption, respectively. However, under certain pathological conditions an imbalance between bone resorption and bone formation may occur, leading to abnormal bone remodeling and the development of bone disorders like osteoporosis.

The diagnosis of osteoporosis is performed by image analysis (principally X-ray and densitometry) but nowadays, there is increasing interest in the use of bone remodeling biochemical markers for clinical applications in bone metabolic disorders. These bone turnover markers (BTM) are substances released into the circulation during the bone formation and/or resorption process, which reflect the metabolic activity of the tissue at a specific time and, therefore, their potential in the evaluation of bone metabolic disorders. The ideal bone remodeling marker should meet the following characteristics: non-invasive determination, ease of sample collection, be an specific product of bone metabolism, show correlation with reference techniques in the bone remodeling analysis such as bone histomorphometry, bone biopsy after double labeled with tetracycline, isotopic studies with labeled calcium and/or dual x-ray absorptiometry and respond to the specific treatment of diseases that affect bone metabolism [ 8 ].

The identification and analysis of these markers is vital for the monitoring of osteoporosis as well as for other bone metabolic diseases, since the use of bone turnover markers allows following the progression of the disease and in addition the therapeutic response of the patient. Moreover, these markers have the capacity to predict the risk of fracture and therefore can be useful in the adoption of certain therapeutic decisions. Thus, several prospective studies examining the relationship between BTMs and subsequent fractures showed that one or more markers of bone turnover (formation or resorption) were significantly associated with fracture risk [ 9 , 10 , 11 ]. Furthermore, in women with a low bone mineral density, the presence of an increase of certain BTMs has an additive effect on fracture risk [ 12 , 13 , 14 , 15 ].

2. Bone Turnover Markers (BTM)

A summary of the main bone turnover markers that exist, their peculiarities and their potential in osteoporosis management are detailed below.

2.1. Markers of Bone Resorption

2.1.1. Amino and Carboxyl-Terminal Cross-Linking Telopeptides of Type I Collagen (NTX and CTX)

Type I collagen is the most abundant protein component of bone, representing 90% of the organic extracellular matrix [ 16 ]. Type I collagen is formed by a triple helix of two molecules of pro-α1 chain, codified by COL1A1 gene; and one pro-α2 chain, encoded by COL1A2 . During bone resorption process, collagen is degraded into different fragments. C- and N-terminal telopeptides of type I collagen (CTX and NTX, respectively) are both fragments from the telopeptide region, a non-triple-helical portion near the ends of mature collagen molecule. Telopeptides are cleaved during osteoclastic resorption of bone and, are released into the blood stream at a rate which is proportional to bone resorption activity [ 17 ].

Two types of proteinases have been described to take part in this process; the cysteine proteinases, which act at acidic pH and matrix metalloproteinases (MMP) that act at neutral pH. Thus, depending on the acting proteinase, one telopeptide molecule or another is released. CTX and NTX are generated from the activity of the cysteine proteinase cathepsin K, while the MMP or trypsin digestion of bone, leads to the release of cross-linked telopeptide of type I collagen (ICTP) [ 18 ]. Actually, CTX, NTX and ICTP molecular markers of type I collagen degradation have been shown to respond differently according to the clinical situations and treatments. This is due to the difference in the enzymatic pathways leading to their release. ICTP levels have been reported to respond more to pathways of bone resorption activated by skeletal metastasis of malignant tumors, multiple myeloma and rheumatoid arthritis [ 17 , 19 ] whereas CTX has been proposed by International Osteoporosis Foundation (IOF) to be used as a reference marker for bone resorption, in the context of fracture risk and therapy monitoring in osteoporosis [ 20 ]. There are diverse assays for measuring CTX, both in urine and in serum, including enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and an electrochemiluminescence assay [ 21 ]. Importantly, CTX levels show a circadian variation with a maximum at 05:00 h and a minimum of about 14:00 h [ 22 ]. This circadian variation is only affected by fasting, which significantly reduced this variation, thus the collection of the sample is recommended in the morning after overnight fasting [ 23 ].

NTX can also be measured in serum or urine, although it is preferentially measured in urine; since urine NTX is more sensitive than serum NTX in detecting changes induced by antiresorptive therapies [ 24 ]. To avoid the variability due to circadian changes in bone turnover, NTX is measured in 24-hour urine samples by ELISA immunoassays (using antibodies that recognize the α2 crosslinked fragment of type I collagen). Besides, NTX levels are less sensitive to dietary intake changes compared to CTX.

2.1.2. Pyridinoline (PYD) and Deoxypyridinoline (DPD) Cross-Links

Pyridinoline (PYD) and deoxypyridinoline (DPD) are covalent pyridinium cross-links that bridge several collagen peptides and mechanically stabilize the collagen molecule [ 25 ]. They are produced from the breakdown of collagen during bone resorption and their levels strictly reflect the degradation of mature crosslinked collagens. PYD and DPD are released into circulation and subsequently excreted in urine either as free or peptide-bound moieties.

PYD is found in numerous tissues such as cartilage, bone, ligaments and vessels, while DPD is only detected in bone and dentin. In any case, the turnover of the bone is much higher than in the aforementioned tissues, so it is considered that the PYD and DPD of both, serum and urine, are produced mostly in the bone tissue. Moreover, since PYD and DPD levels are not altered by food intake, pyridinium crosslinks are viewed as good markers of bone resorption. Both free and conjugated forms of PYD and DPD have been shown to be stable in urine samples kept at room temperature for several weeks. If storage occurs at −20 °C they can last for years, the repeated freeze-thaw cycles of urine samples have no effect on their concentrations [ 26 ].

Pyridinium cross-links can be detected and quantified by automated high-performance liquid chromatography (HPLC) [ 27 ], direct immunoassays for free and peptide-bound forms [ 28 , 29 ], as well as by liquid chromatography tandem mass spectrometry (LC–MS/ MS) [ 30 ].

2.1.3. Hydroxyproline (OHP)

Hydroxyproline (OHP), an amino acid formed from the post-translational hydroxylation of proline, constitutes 12–14% of the total amino acid content of mature collagen [ 31 ]. During the bone degradation process, OHP is released and 90% of it reaches the liver, where it is metabolized and finally excreted in the urine, either in free form or linked to peptides [ 32 ]. Hydroxyproline can be measured by colorimetric assays or HPLC methods [ 33 , 34 , 35 ].

Although urinary OHP is considered a bone resorption marker it should be taken cautiously since significant amounts of OHP in the urine proceed from newly synthesized procollagen during bone formation process [ 36 ]. Furthermore, hydroxyproline can be found in other tissues like skin and cartilage, being also released from the metabolism of elastin and complement component 1q (C1q) protein [ 37 , 38 ]. These drawbacks prevent OHP from being considered as a specific marker for bone resorption and it has been replaced by other biomarkers that show higher specificity in osteoporosis monitoring [ 39 ].

2.1.4. Hydroxylysine-Glycosides

Hydroxylysine is produced during the synthesis of collagen due to the post-translational modifications suffered by collagen. Subsequently, hydroxylysine can undergo additional modifications like glycosylation giving rise to two different forms; glucosyl-galactosyl-hydroxylysine (GGHL) and galactosyl-hydroxylysine (GHL). The glycosilation of the hydroxylysine is different depending of the tissue; GHL is specific for bone, while GGHL is the major form in skin [ 40 ]. Although hydroxylysine is found in all collagens, GHL is five-to seven fold more concentrated in type I collagen of bone than in type I collagen of skin [ 41 ].

Both of them are released into the circulation during collagen degradation and can be measured in the urine by HPLC after derivatization with a fluorescence compound [ 42 ]. Later, an immunoassay for urinary GHL was developed based on polyclonal antibodies [ 43 ].

The glycosylated forms of hydroxylysine are not metabolized before excretion in urine, as the case with hydroxyproline, nor are they affected by dietary intake. It has been estimated that urinary hydroxylysine glycosides represent the 50–100% of collagen breakdown, a much higher percentage than the estimated for OHP [ 44 ]. Therefore, since the 90s it has been regarded as a better marker than OHP [ 45 , 46 ].

2.1.5. Tartrate-Resistant Acid Phosphatase (TRACP5b or TRAP5b)

This enzyme belongs to the ubiquitous family of the acid phosphatases. There are five isoforms which are expressed in different cell types. All acid phosphatases are inhibited by L (+)-tartrate, except form 5, so the latter it was called tartrate resistant acid phosphatase (TRAP or TRACP). There are two TRACP subforms—type 5a, which contains sialic acid and type 5b, which does not, the latter being characteristic of osteoclasts [ 47 ]. In fact, this TRACP5b is accepted as a marker of both: the number of osteoclasts and their activity [ 48 , 49 ]. It presents low diurnal variability and is not affected by feeding [ 50 ], being typically increased in high bone turnover conditions [ 51 ]. There are specific immunoassays for serum TRACP5b detection, actually it has been proposed for the evaluation of BMD in women [ 52 ].

TRACP5b stability goes as follow: serum samples can be kept for 2 days at room temperature and for 3 days at 4 °C. However, for longer storage, freshly collected samples should be stored in aliquots at −20 °C for a maximum of one month or at −70 °C to remain stable for years [ 53 ].

2.1.6. Bone Sialoprotein (BSP)

Bone sialoprotein, an important extracellular glycoprotein of mineralized tissues, represents the 5–10% of the non-collagenous matrix of bone. Although its theoreticalmolecular weight (MW) is 33 kDa, due to different post-translational modifications (N and O-linked glycosylation, serine and threonine phosphorylation, tyrosine sulfation and sialylation) it has an apparent MW of 60–80 kDa [ 54 ]. BSP is produced by many different cell types during bone morphogenesis such us osteoblasts, osteoclasts, osteocytes and hypertrophic chondrocytes [ 55 , 56 ]. In fact, this protein is considered to play an important role in cell-matrix adhesion processes and in the supramolecular organization of the extracellular matrix of mineralized tissues [ 41 ].

Serum BSP can be measured by different immunoassays [ 57 ]. Several studies show that BSP levels might be a useful marker in laboratory assessment of bone turnover since it shows a significant correlation to established markers of bone formation like bone alkaline phosphatase (B-ALP) and osteocalcin (OC) [ 58 ], to bone resorption markers such as PYD, DPD, NTX as well as bone resorptive cytokines interleukin-11 (IL-11) and transforming growth factor β2 (TGFβ2) [ 59 ]. Based on the rapid reduction of serum BSP levels following intravenous bisphosphonate treatment, it is considered to reflect bone resorption processes [ 31 ].

2.1.7. Cathepsin K

Cathepsin K is a protein of 329 amino acids form by a long N-terminal signal sequence of 15 amino acids, a 99 amino acid long propeptide and a 215 amino acid long catalytic unit [ 60 ]. This protein is a member of the cysteine protease family, being able to cleave both helical and telopeptide regions of type I collagen [ 61 ]. Cathepsin K is predominantly expressed in osteoclasts and other multinucleated cells. Immunocytochemical studies have shown that it is located in various intracellular compartments of the osteoclasts such as vesicles, granules and vacuoles. Later, it is secreted into the extracellular environment, specifically into the bone resorption lacuna underneath actively resorbing osteoclasts, where it is responsible for the degradation of type I collagen [ 62 ]. Therefore, cathepsin K and specifically its circulating form, may be a useful and specific biochemical marker of osteoclastic activity [ 31 ]. Likewise, it has been demonstrated its relevance for osteoporosis, given that bone resorption associated with cysteine protease and cathepsin K by osteoclasts is negatively regulated by estrogens [ 63 ]. Moreover, the osteoclastogenic factor receptor activator for nuclear factor kappa B ligand (RANKL) appears to directly up-regulate cathepsin K expression [ 64 ]. There are several immunoassays available to measure cathepsin K levels in serum samples [ 65 ]. In addition, it is also possible to quantify the activity of the protein by means of a synthetic substrate that, when metabolized, releases a fluorescent compound [ 66 ].

2.2. Markers of Bone Formation

2.2.1. Serum Osteocalcin

OC, also known as bone γ-carboxyglutamic acid-containing protein (BGLAP), is a non-collagen protein of 5.8 kDa. Although non-collagen proteins represent only 10% of the organic extracellular matrix, their roles in the regulation of bone turnover and mineralization are essential [ 67 , 68 ]. OC is synthesized by mature osteoblasts, being the most abundant non-collagenous bone matrix protein (15% of total non-collagen proteins) [ 69 ]. Although the function of OC is not completely elucidated, it might have a role in the regulation of osteoblasts function, as suggested by knockout mouse models. Surprisingly, at six months of age, OC −/− mice showed a marked increase in bone formation, increased cortical and trabecular thickness, seeming their bones mechanically more stable than those of the wild type mice [ 70 ].

OC is often used as a marker for late bone formation [ 71 ]. It is synthesized and secreted by osteoblasts, later being incorporated in bone extracellular matrix. However, during this process a small fraction is released into the blood stream being detectable by immunoassay. Serum OC have shown to correlate with bone formation rate [ 72 , 73 ]. However, serum OC is rapidly degraded even at temperatures as low as 4 ·C, resulting in OC fragments that can be detected by antibody based assays along with the full-length molecule. The detection of intact OC or its fragments is an important issue to be aware of, since tests that detect only intact OC will be particularly sensitive to in vitro degradation, while tests that detect fragments may, according to the recognized fragments, overestimate the concentration of intact OC [ 74 ].

Serum OC presents a high biological and circadian variability, which might negatively affect the reproducibility of repeated measures. Either RIA, ELISA or a chemiluminescence immunoassay may be used to detect OC in serum [ 75 , 76 ].

2.2.2. Serum Alkaline Phosphatase and Bone-Specific Alkaline Phosphatase

Alkaline phosphatases (ALPs) are plasma membrane-bound glycoproteins. Human ALPs can be classified in four tissue-specific isoforms; placental alkaline phosphatase (PLALP or Regan isozyme), intestinal alkaline phosphatase (IALP), tissue nonspecific alkaline phosphatase (TNAP) and germ cell ALP (GCALP or NAGAO isozyme) [ 77 ]. The tissue non-specific ALP gene encodes kidney, liver and bone isoforms of ALP. In healthy individuals, bone and liver specific ALP constitute 95% of the total ALP activity found in serum. In adults, both isoforms are normally present at equal proportion (1:1) [ 40 ]; however, during childhood and adolescence, due to skeletal growth, bone isoform is predominant (up to 90%) [ 78 ]. Bone specific ALP is generated by osteoblasts during bone formation. Although its exact function is not completely elucidated, it is known that ALP presence in osteoblasts cell membrane is necessary for bone mineralization [ 79 ] and ALP expression correlates positively with bone formation rate [ 80 ].

In order to differentiate between the two main circulating ALP isoforms, several techniques have been developed; namely, heat denaturation, electrophoresis, precipitation, selective inhibition and immunoassays [ 81 ]. Nonetheless, immunoassays show certain degree of cross-reactivity and subjects with high liver ALP, can result in artificially high bone ALP measurements, leading to false positive results [ 82 ].

2.2.3. Serum PINP and PICP

N-terminal and C-terminal propeptide of type I procollagen (PINP and PICP, respectively), are released from posttranslational modifications that type I procollagen molecule suffers during collagen assembly into fibrils [ 83 ]. Both molecules are produced in equimolar amounts with each other and with the collagen deposited in the tissue.

PINP has 70 kDa and is rich in proline and hydroxyproline, which are essential for the triple helical structure stability. PINP is eliminated from the circulation by liver endothelial cells through their scavenger receptors [ 84 ]. PINP primarily originates from bone but other tissues like skin, tendon, dentin, ligaments, cartilage and interstitial tissue also contribute to PINP serum levels [ 85 ]. Serum PINP concentrations reflect the new skeletal bone formation, therefore, diseases that involve high bone turnover would be expected to be associated with high serum concentrations of PINP. Normally, PINP is present in serum in two forms; an intact trimeric form and a monomeric form. The two PINP forms have different catabolic routes; trimeric PINP is rapidly cleared from blood circulation by scavenger receptors on liver endothelial cells [ 84 ], while monomeric form clearance mechanism is still poorly understood. However, it is probably cleared via kidneys, as shown by the similar monomeric fragment of amino-terminal propeptide of type III collagen [ 86 ]. Both forms can be detected together by the “total” PINP assay whereas the “Intact” PINP assay, only detects the trimeric form [ 83 ]. In addition, the measurement can be performed by both automatic and manual methods like RIA, ELISA and electro-chemiluminescence immunoassays. Serum PINP is quite insensitive to food intake and the circadian rhythm, in clinical trials, this marker has been shown to increase dynamically in response to treatment with teriparatide [ 87 ], an anabolic drug that increases bone formation. PINP is stable in serum/plasma for at least five days at room temperature and for four weeks at 4 °C [ 88 ].

The other molecule—PICP—consists of 115 kDa and it is produced in the same way that PINP during collagen synthesis in bone formation processes. PICP is stabilized by disulphide bonds and is cleared by liver endothelial cells via the mannose receptor which can be regulated by growth and thyroid hormones [ 89 ]. PICP presents a short serum half-life of only 6–8 minutes, which limits its use as biomarker.

PINP, on the other hand, presents a longer stability in serum besides being no affected by food intake and circadian rhythm. All of that, point this molecule as a remarkable biomarker. In fact, PINP has been recommended as the bone formation marker by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry (IFCC) for clinical research studies in osteoporosis [ 90 ]. Likewise, the National Bone Health Alliance has also recommended PINP as the reference marker for bone formation [ 91 ].

3. Osteoporosis Treatments

A healthy and active lifestyle is vital for the proper maintenance of all body tissues, including bone. Several studies have highlighted the importance of physical exercise to improve the quality of life of patients with osteoporosis [ 92 , 93 , 94 ]. Recently, Filipović, T. et al. 2020 [ 95 ], has demonstrated that exercising is able to modulate the enzymatic activity of serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in postmenopausal osteoporotic patients.

Diet also plays a fundamental role in bone health. Calcium supplementation has been shown to be able to decrease the rate of bone mineral density loss in women, although it does not seem to be enough to prevent fractures [ 96 ]. The combination of calcium with vitamin D showed better results, with a reduction of 15% in the risk of total fractures and 30% in the risk of hip fractures [ 97 ]. During menopausal transition, the drop of endogenous estrogens enhances bone resorption, at the expenses of the new bone formation, leading to osteoporosis [ 98 ]. In consequence, estrogen intake could be an appropriate therapy against osteoporosis. However, estrogen therapy is associated with elevated cancer risk in estrogen receptor (ER)-α rich tissues like the endometrium, breast and ovary. Therefore, alternative molecules have been sought to prevent this unwanted effect of estrogen therapy. In that matter, isoflavones are a type of phytoestrogens that have shown a weak binding to ERα [ 99 ] and preferentially bind to ER-β; present in bone, liver, heart and brain. Therefore, they mimic the effects of estrogens in some tissues and at the same time, block the estrogen effects in others. Isoflavones can be absorbed through the diet in legumes (most importantly in soy), nuts and some fruits. Recently, in a randomized clinical trial, isoflavone treatment has achieved a decline in the BMD loss, together with an increased in bone turnover. Moreover, the combination of this phytoestrogens with calcium, magnesium and calcitriol showed even better results [ 100 ]. However, its effectiveness remains controversial since a meta-analysis of 10 long term clinical trials concluded that soy isoflavones did not show significant improvement in lumbar spine, total hip or femoral neck BMD of postmenopausal women [ 101 ]. Altogether, these approaches are insufficient to prevent the progression of osteoporosis. Therefore, pharmacological therapies have been developed to counteract bone fragility based on molecular targets [ 102 ]. Therapies for osteoporosis are focus on restoring the normal balance between bone resorption and bone formation. Currently, the most common therapies are the anti-resorptive ones, focusing on the inhibition or reduction of bone resorption process. These agents include estrogens, selective estrogen receptor modulators (SERMs), bisphosphonates and monoclonal antibodies [ 103 ].

Bone resorption is highly determined by hormone levels, such us estrogens. As mentioned above, unopposed estrogen can increase the risk of breast and uterine cancers, deep vein thrombosis and stroke [ 104 ]. Therefore, in order to reduce the side effects of estrogens, SERMs have taken a step forward. Although they demonstrate selectivity toward estrogen receptors in the bone and are able to maintain bone mineral density (BMD), they lack the efficacy of traditional estrogens [ 105 ]. Many clinical trials with postmenopausal osteoporotic women using different types of SERMs have shown that their benefit for fractures prevention is anatomically limited (present certain limitations in preventing non-vertebral fractures). In addition, SERMs are also associated with detrimental extra-skeletal effects such as an increased risk of a cardiovascular event and endometrial cancer risk [ 106 ], as well as related side effects such as thromboembolic events and, in some cases, carcinogenesis [ 107 ].

Among anti-resorptive drugs, the most used are bisphosphonates. Bisphosphonates are pyrophosphate analogues that bind to hard bone through their affinity for hydroxyapatite [ 108 ]. They are incorporated into bone matrix and taken up by osteoclasts, suppressing their activity in bone remodeling [ 109 ]. This way, the bone density increases but the quality of the bone is compromise since the old bone is prone to have microfractures that negatively affect its function. Moreover, the prolonged use of bisphosphonates may lead to adverse events, such as gastrointestinal problems, osteonecrosis of the jaw, atrial fibrillation and musculoskeletal pain [ 110 , 111 ].

Denosumab is a monoclonal antibody that binds with high affinity to receptor activator of nuclear factor kappa-Β ligand (RANKL), preventing the binding between RANKL and receptor activator of nuclear factor kappa-Β (RANK) and thus inhibiting the differentiation and activity of the osteoclasts [ 112 ]. Unlike bisphosphonates, Denosumab is not incorporated into bone, yielding a much shorter terminal half-life [ 113 ]. Consequently, Denosumab presents a potential advantage for the patients who have a side effect for the therapy, due to the fact that it will be no longer active six months after the last dose. A big concern regarding Denosumab treatment is the regular adhesion to this treatment, because the patient’s fracture risk might increase after the dose “wears off” [ 114 ].

Although anti-resorptive osteoporosis medications reduce fractures, they have rare and serious adverse effects that may limit their safety for medium and long-term use, so new safe therapies capable of restoring skeletal structure and integrity are needed. In fact, current pharmacologic attempts for osteoporosis aim to prevent fractures through stimulation of bone formation. These agents target anabolic pathways to stimulate the osteoblastic activity, increasing the bone volume without inhibiting its resorption.

The first approved agent to accomplish this was teriparatide. Teriparatide is a recombinant human parathyroid hormone (PTH), known to be the only available therapeutic agent that increases the formation of new bone tissue [ 115 ]. PTH regulates the amount of calcium in bone; therefore this treatment is used to stimulate osteoblasts to create new bone [ 116 , 117 ]. Toxicological studies revealed osteosarcoma in treated rats; nonetheless this problem has not been detected in treated patients. As a consequence, the approved lifetime duration of treatment with teriparatide is 24 months; but it is recommended only for patients for whom potential benefits outweigh potential risk [ 118 , 119 ].

Romosozumab, is another monoclonal antibody recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women. The registered trade name of Romosozumab is Evenity. It is the first humanized anti-sclerostin monoclonal antibody that has been shown to increase bone formation with dual effect: on one hand, it increases bone formation and, on the other, although to a lesser extent, it reduces bone resorption (or bone loss) which translates into a decrease in the risk of fracture [ 120 ]. However, according to the prescribing information; it may increase the risk of myocardial infarction, stroke and cardiovascular death. Therefore, it should not be administered to patients who have had a myocardial infarction or stroke within the preceding year.

Sclerostin, expressed by osteocytes and articular chondrocytes, is the product of SOST gene. It is an endogenous inhibitor of the Wingless-type mouse mammary virus integration site (Wnt) signaling pathway. Wnt signaling has been described as a positive regulator of bone formation and regeneration [ 121 ] and thus, Wnt signaling could be modulated to treat osteoporosis and other skeletal diseases associated with low BMD and increased facture risk [ 122 ]. Therefore, anti-sclerotin compound would inhibit sclerostin (an inhibitor of Wnt signaling) and in consequence, promote Wnt signaling and stimulate bone formation by osteoblasts [ 123 ]. Another two anti-sclerostin monoclonal antibodies are being developed by other companies; blosozumab (Eli Lilly and Company, Indianapolis, IN, USA) and BPS804 (Novartis, Basel, Switzerland).

In summary, currently used osteoporosis therapies are not fully effective in all patients and present considerable side effects that seriously compromise their long-term use. Thus, the development of new therapeutic strategies for osteoporosis is craved in an increasingly aging world population with a longer life expectancy.

4. Mesenchymal Stem Cells

As mentioned before, current attempts for developing safe new therapies are focused on anabolic therapeutic strategies, able to increase the activity of new bone forming cells (osteoblasts) and/or their progenitor.

The osteoblasts progenitors, named as mesenchymal stem cells (MSCs) are spindle shaped cells with multipotent differentiation capacity in vitro. The International Society for Cellular Therapy (ISCT) has proposed minimum criteria to define MSCs. These cells (i) should exhibit ex vivo plastic adherence under normal conditions (ii) possess specific immunophenotype, such as the expression of CD73,CD90,CD105 and lack of CD14, CD34, CD45 and human leukocyte antigen-DR (HLA-DR) (iii) have the ability to differentiate into osteogenic, adipogenic and chondrogenic lineages in vitro [ 124 ].

The study of MSCs and the pathways involved in adipogenesis, osteogenesis and chondrogenesis [ 125 ], have contributed to the understanding of the mechanism that leads into an osteoporotic phenotype.

In healthy individuals, the rate of MSCs in bone marrow is very low (about 0.01 %–0.001 %) [ 126 ], being even lower in aged population. If, in addition to this, the aged MSCs lose their capacity to suitably proliferate and differentiate being the subsequent bone formation compromised, there is a high risk of developing osteoporosis [ 127 ]. Moreover, osteoporosis could be caused, at least in part, due to the preferential differentiation of MSCs into adipocytes instead of osteoblasts in the aging skeleton [ 128 ]. Many different studies have compared the functional characteristics of MSCs from osteoporotic patients versus controls; MSCs from osteoporotic women present a lower growth rate than control cells [ 129 ], together with decreased TGF-β production and decreased capacity to generate and maintain a type I collagen-rich extracellular matrix [ 130 ]. Both conditions support the hypothesis that MSCs from osteoporotic patients have an increased tendency to differentiate into adipocytes [ 131 ]. Supporting this observation, cells derived from osteoporotic donors have diminished ALP activity [ 129 ] and calcium deposition under osteogenic differentiation conditions.

MSCs fate determination is regulated by specific transcription factors [ 132 , 133 ] and intrinsic signals [ 125 ], such as runt-related transcription factor 2 (Runx2) [ 134 ] and osterix (Osx) for osteoblasts differentiation; and peroxisome proliferator activated receptor gamma (PPARγ) for adipocytes [ 135 , 136 ]. Interestingly, these regulators have been found to be altered in osteoporotic MSCs leading to functional alterations that result in poor osteogenic differentiation capacity and increased adipogenesis [ 137 , 138 ].

In addition, hMSCs from patients with osteoporosis and age-matched controls have been shown to exhibit different transcriptomes. Osteoporotic MSCs show an enhanced mRNA expression of genes involved in osteoclastogenesis (VEGF, TGFB and CSF1) and genes coding for inhibitors of Wnt and bone morphogenetic protein (BMP) signaling, indicating intrinsic deficiencies in self-renewal and differentiation potential of osteoporotic stem cells [ 139 ].

5. Therapeutic Potential of Mesenchymal Stem Cells

Given the diminished proliferation and differentiation ability of MSCs from osteoporotic patients, it is quite reasonable to contemplate the benefits of providing healthy MSCs to the patients to boost the bone anabolic pathway. Numerous efforts have been attempted in the field of cellular therapy based on MSCs applied to osteoporosis. In the beginnings, the cell therapy potential was focus on MSCs´ ability to target a damaged site and subsequently, to differentiate into osteoblasts in order to repair the degenerated tissue. However, the poor engraftment demonstrated by transplanted cells in humans [ 140 ] generates a serious questioning regarding the limitation of this mechanism of action. A more consensus mechanism of action relays on their ability to act in a paracrine manner by secreting factors that modify the environment and recruit resident cells to repair the degenerated tissue [ 141 ].

However, a recent murine study [ 142 ] has demonstrated the capability of healthy Bone-Marrow derived MSCs to engraft in osteogenesis imperfecta (OI) mouse model improving bone phenotype. OI is a rare bone disorder characterized by bone fragility like osteoporosis. The direct intra-bone transplantation of bone-marrow MSCs achieved long-term engraftment (up to 6 months post-transplantation), with the consequent improvement of cortical structure and strength in mouse bone. The greater efficiency of this study compared to the one mentioned above [ 140 ] may be due to the mode in which MSCs are administered considering that, in the previous treated OI pediatric patients MSCs were intravenously infused. Thus, different routes of MSCs administration should be further investigated in order to improve MSCs effectiveness in the treatment of bone metabolic disorders.

5.1. Mesenchymal Stem Cells from Different Origins as a Novel Therapy for Osteoporosis

The MSCs used to treat osteoporosis could have different origins: Bone-Marrow derived MSCs (BM-MSCs), adipose-tissue derived MSCs (AD-MSC) or umbilical cord derived MSCs (UC-MSCs). Although all of them have shown therapeutic effects for osteoporosis in preclinical studies, there are still some challenges on their clinical application, such as the limited long-term survival and the uncertainty of MSCs´ fate after transplantation depending on the source of MSCs [ 140 , 143 ].

5.1.1. Bone Marrow Derived MSCs (BM-MSCs)

Several studies in animal models intended to prove the potential of transplanted BM-MSCs to treat osteoporosis, both from allogenic and autologous sources.

Different osteoporotic murine models have been used to demonstrate the therapeutic capacity of MSCs. Ichioka and collaborators [ 144 ] used an irradiated P6 substrain of senescence-accelerated mice (SAMP6), which is an osteoporotic mouse model that exhibits age-dependent restraint of osteoblastogenesis and osteoclastogenesis along with enhanced adipogenesis. The authors demonstrated that locally administration of normal murine allogeneic BM-MSCs could increase trabecular bone and attenuate BMD loss [ 144 ].

Ovariectomy (OVX)-induced rat model has also been used to challenge the potential of MSCs to treat osteoporosis. Allogenic BM-MSCs isolated from healthy rats were injected into the femurs of osteoporotic rats. The femurs of treated rats showed trabecular bone percentage almost similar to the femurs from control healthy rats. As expected, osteoporotic BM-MSCs showed less differentiation capabilities as compared to those isolated from healthy rats [ 145 ].

Glucocorticoid-induced osteoporosis mouse model has also been applied to study the effect of the systemic injection of allogeneic BM-MSCs. The encouraging outcomes comprised inhibition of the decrease of bone mass and strength as well as stimulation of osteoblastogenesis, with consequent sustained bone formation [ 146 ].

Finally, Kiernan, Hu, Grynpas, Davies, & Stanford (2016) [ 147 ] made use of an age-related osteoporosis mouse model, Sca-1 −/− , to demonstrate that systemic administration of allogeneic bone marrow MSCs, noticeably improved bone formation and maintained the microarchitectural capability.

In addition, further non-murine animal models have been used to study the beneficial effect of BM-MSCs injection to treat osteoporosis. Autologous BM-MSCs had been transplanted in an OVX-induced rabbit model of osteoporosis, displaying more bone apposition, stronger stiffness of bone, raised trabecular thickness and developed microstructures with freshly formed osteoids [ 127 ]. Similar effects were obtained when BM-MSCs were injected in goats with long-term estrogen deficiency (mimicking the postmenopausal osteoporosis that occurs in humans) [ 148 ].

Phase I clinical trial is currently ongoing, where autologous fucosylated (a type of glycosylation) BM-MSCs are infused into osteoporotic patients. However, there is some uncertainty regarding the use of autologous BM-MSCs for osteoporosis treatment in elderly patients, due to the age-related decline in the overall BM-MSC number [ 143 , 149 ] (ClinicalTrials.gov Identifier: NCT02566655 ).

5.1.2. Adipose Tissue-Derived MSCs (AD-MSCs)

Adipose tissue-derived MSCs have become increasingly popular in many stem cell applications since they are more easily isolated, more abundant and produce higher yields in terms of cell number compared with BM-MSCs [ 150 ]. However, the efficiency of AD-MSCs and their proliferative and differentiation capacities vary depending on the tissue harvesting site [ 151 ] and in a similar way to BM-MSCs, on the donor age [ 152 ].

Different animal models had also been utilized to study the efficiency of AD-MSCs to treat osteoporosis. SAMP6 age-related osteoporotic mice had been transplanted with isogenic AD-MSCs, resulting in a significant improvement in several trabecular bone parameters [ 153 ]. Cho and collaborators focused on preventing OVX-induced bone loss in nude mice by injection of human AD-MSCs; reassuring remarkable rise in BMD was seen in the mice [ 154 ].

Additional encouraging studies based on OVX-induced rabbit models of osteoporosis transplanted with autologous AD-MSCs shown enhanced bone regeneration, due to their capacity to stimulate osteogenesis and prevent adipogenesis of osteoporotic BM-MSCs. These encouraging outcomes were achieved through activation of bone morphogenetic protein 2 (BMP-2) and the bone morphogenetic protein receptor type 1B (BMPR-IB) signal pathway [ 155 ].

5.1.3. Umbilical Cord Derived MSCs (UC-MSCS)

BM- and AD-MSCs are effective sources of MSCs but their therapeutic potential can be affected by the donor’s lifestyle and age. Thus, bone regenerative medicine has focused its efforts on finding new sources of MSCs in perinatal tissues, such us umbilical cord [ 156 ]. These cells are younger than adult BM-and AD-MSCs, have strong osteogenic differentiation ability, demonstrated few immunogenic adverse effects and have an easy and noninvasive harvesting procedure without any risk to the donor [ 157 , 158 ].

Bone formation by umbilical cord-derived MSCs (UC-MSCs) was demonstrated in vivo by Diao and collaborators who loaded human UC-MSCs into scaffolds that were transplanted subcutaneously into BALB/c nude mice, observing efficiently bone formation by UC-MSCs [ 159 ]. An et al. (2013) [ 160 ] used OVX nude mice as a model to study the influence of systemic injection of human umbilical cord blood hUCB-MSCs. After the infusion, the BMD levels enhanced considerably and the micro-CT analysis of the mice tibiae exhibited considerably greater values of trabecular number and thickness, as well as bone volume.

So far, there are no clinical trials with UC-MSCs cells applied to osteoporotic patients.

6. Bone Turnover and Inflammation

Emerging clinical and molecular evidence suggests that inflammation exerts significant influence on bone turnover, thereby in osteoporosis. Estrogen deficiency is the main cause of osteoporosis in post-menopausal women. This condition results in increased production of inflammatory cytokines, describing osteoporosis as an inflammatory disease [ 161 , 162 , 163 ]. Estrogen has a protective effect in bone, due to a direct action on osteoclasts and osteoblasts. Regarding osteoclasts, estrogens significantly increase their apoptosis [ 164 , 165 ] and reduce the RANKL-dependent osteoclast formation [ 166 ]. In osteoblasts, they exert an anabolic effect by at least increasing osteoblast survival and collagen type I production [ 167 ]. Estrogens has been demonstrated to also modulate lymphocytes; its presence suppresses RANKL production in T and B lymphocytes [ 168 ], the lack of estrogens increases the release of pro-osteoclastogenic cytokines (tumor necrosis factor α (TNF-α) and RANKL) by activated T lymphocytes [ 169 , 170 ] and are also associated to an increase in B lymphocytes number [ 171 ].

Bone fractures repair is mediated not only by the bone but also with the aid of the immune system, being crucial in the process [ 172 ]. In fact, human immunodeficiency virus (HIV) patients, who are immunologically compromised, show a delay of fracture healing process [ 173 ] and B and T cell depletion has been reported to be associated with bone regeneration impairment, due to a reduction in osteoblast differentiation and bone mineralization [ 174 ].

The first phase of bone healing is characterized by an acute inflammatory response; the release of interleukin-1 (IL-1), interleukin-6 (IL-6) and TNF-α recruits B and T lymphocytes. T lymphocytes have a pro-osteogenic role, by releasing interleukin-17F (IL-17F) [ 175 ]. This cytokine promotes Col1a1, osteocalcin and sialoproteins in osteoblasts [ 175 ]. After that, immune cells produce chemoattractant molecules like CXCL7 (NAP2) and monocyte inflammatory protein (MIP)-1 alpha. Once bone repair process has started, the inflammatory response must be stopped to avoid more damage. To this end, MSCs stimulate the differentiation of the T-reg lymphocytes, inducing the apoptosis of the pro-inflammatory Th1 and Th17 lymphocytes and inhibiting migration of B cells.

7. MSCs Immunoregulatory Capabilities

MSCs have been shown to possess immunoregulatory abilities [ 176 ], being capable of interacting with cells of both adaptive and innate response: B cells, T cells, dendritic cells (DCs), natural killer (NK) cells, neutrophils and macrophages [ 177 ]. These immunomodulation relies on cell-cell contact in collaboration with the secretion of soluble immune factors [ 178 ] namely; TGFβ1, hepatocyte growth factor (HGF), indoleamine-2, 3-dioxygenase, prostaglandin E2 (PGE2), interleukin-10 (IL-10), HLA-G5 and galectins.

MSCs have been broadly demonstrated to be able to modulate the differentiation, function and balance of T cells subpopulations (Th1, Th2, Th17 or Tregs) and promote the development of an anti-inflammatory immune response [ 179 ]. Indeed, MSCs constitutively secrete B7-H4 molecule and human leukocyte antigen G (HLA-G), which presents an immunosuppressive action on T lymphocytes, hindering proliferation and cellular mediated cytotoxicity [ 180 ]. With respect to adaptive humoral immunity, MSCs reduce B-cell proliferation by inducing cell cycle arrest in the G0/G1 phase [ 181 ]. They can also affect B-cell differentiation and immunoglobulin synthesis (IgM, IgG and IgA) by the release of metalloproteinase-processed CC-chemokine ligand 2 (CCL2) [ 182 , 183 ].

MSCs have been demonstrated to exert an immunosuppressive function on dendritic cells (DCs), which are considered the bridge between innate and adaptive immune system. They can inhibit DCs differentiation and maturation in a reversible manner [ 184 , 185 ]. MSCs have also the ability to decrease the production of the pro-inflammatory cytokines (such as interleukin-12 (IL-12) [ 186 ] and TNF-α), as well as to up-regulate the production of the anti-inflammatory cytokine IL-10 in monocytes [ 187 ]. Therefore, MSCs are able to impair both the antigen presentation function and the pro-inflammatory potential of DCs. In fact, allogeneic UC MSCs seems to suppress inflammation in lupus erythematosus patients though up-regulating tolerogenic DCs [ 188 ].

As for the innate immune system, some studies have shown that MSCs are capable of inhibiting NK cell proliferation, cytokine release and cytotoxicity, via prostaglandin E2 and indoleamine dioxygenase [ 187 , 189 ]. The inhibitory effect on the effector functions of NK cells is produced by a sharp down-regulation of the surface expression of the activating NK receptors NKp30, NKp44 and NKG2D. Later, Thomas and co-workers 2014 [ 190 ] showed that in the proper conditions, MSCs may also support NK cell function. MSCs enhance the IFN-γ secretion by NK cells in the presence of the pro-inflammatory cytokines IL-12 and IL-18. Both cytokines are frequently expressed during the immune response to pathogens. Therefore, it is possible that MSCs, when present at the site of infection support the elimination of invading pathogens through the stimulation of NK cells for increased IFN-γ production. But not only NK cells, MSCs also support neutrophils function by promoting their viability and enhancing their recruitment and activity in proinflammatory situations. MSCs, even at very low proportions in vitro (MSC: neutrophils at 1: 500), are able to inhibit apoptosis of both, resting neutrophils and IL-8 activated ones. In addition, they reduce the respiratory burst induced by N-formyl-l-methionine-l-leucyl-l-phenylalanine (f-MLP) without affecting other processes like phagocytosis, expression of adhesion molecules or neutrophil migration capacity in response to classical stimuli [ 191 ]. In addition, this study also showed that MSCs by constitutive release of IL-6 rescued neutrophils from apoptosis. Another study in mice showed that when tissue-resident MSCs recognize microbial molecules it results in increased production of growth factors, such as IL-6, interleukin-8 (IL-8), granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage migration inhibitory factor (MIF), that recruit neutrophils and enhance their pro-inflammatory activity [ 192 ]. In a later study, in a murine model of sepsis it was shown that the infusion of MSCs helped bacterial elimination through the improvement of phagocytic activity of neutrophils [ 193 ].

Lastly, increasing evidences have shown that the regulation of macrophages by MSCs is essential for the inflammatory response and tissue lesions repair. It has been reported that MSCs can interact with monocytes and macrophages to reprogram them [ 194 ]. When MSCs are activated by pro-inflammatory signals (produced by M1 macrophages or activated T cells), they can introduce two negative feedback loops into the generic pathway of inflammation [ 195 ]. In one loop, the activated MSCs secrete prostaglandin E2 (PGE2) that drives resident macrophages with an M1 pro-inflammatory phenotype towards an M2 anti-inflammatory phenotype [ 196 ]. It has been demonstrated that when macrophages and MSCs are cocultured, the production of M2 macrophages is induced. Hence, the phagocytic activity and secretion of IL-10 is upregulated and levels of inflammatory cytokines (interferon γ (IFNγ), TNF-α, IL-1β and IL-12) downregulated [ 197 ]. This way, MSCs modulate the preferential shift of the macrophage phenotype from M1 to M2 [ 198 ]. In the second loop, there is a negative feedback that let MSCs to serve as regulators of the early phases of inflammation. When MSCs are activated, they secrete TNFα stimulated gene/protein 6 (TSG-6) that interacts with macrophages to decrease TLR2/NFκ-B signaling, so a decrease in the secretion of pro-inflammatory mediators occurs [ 199 ]. These data underline the importance of the interactions between MSCs and the innate immune system in balancing pro-inflammatory and anti-inflammatory responses in order to preserve tissue integrity [ 200 ].

In summary, these results demonstrate the regulatory role of MSCs in the innate and adaptive immunity, due to their ability to down-regulate the intensity of an immune response. Since inflammation seems to significantly contribute to the etiopathogenesis of osteoporosis [ 201 ]; it is plausible to think, based on previous data that MSCs could help to decrease inflammation in osteoporosis patients.

8. Final Considerations

Osteoporosis is a skeletal disorder increasingly recognized as a major public health problem. Current osteoporosis treatments are no safe for long-term use, so the development of new therapeutic strategies is needed. MSCs are increasingly considered as promising tools as a new therapeutic strategy to treat osteoporosis, mainly due to its ability to secrete factors that are directly or indirectly involved in bone repair; as well as, its ability to graft into tissues and differentiate into functional osteoblasts. Emerging evidence suggests that inflammation exerts significant influence on bone turnover, thereby in osteoporosis. In fact, MSCs also have the capacity to interact with different immune cells, so the immunomodulatory capacity of MSCs could be an interesting approach to treat osteoporosis.

Author Contributions

I.M. and N.A.-S. writing original draft, A.I. and C.I.R.; revising and editing of the manuscript, C.I.R.; funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

This study has been funded by: Instituto de Salud Carlos III through the projects No. PI15/00820 and PI18/00202 (Co-funded by European Regional Development Fund/European Social Fund; “A way to make Europe”/“Investing in your future”) and Basque Country government under the ELKARTEK program, No. kk-2018/00031/BC and No.kk-2019/00093/BC.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript or in the decision to publish the results.

Abbreviations

References

1. Cauley J.A. Public health impact of osteoporosis J. Gerontol. A Biol. Sci. Med. Sci. 2013 68 1243 1251 10.1093/gerona/glt093 23902935 PMC3779634

2. Svedbom A. Hernlund E. Ivergård M. Compston J. Cooper C. Stenmark J. McCloskey E.V. Jönsson B. Kanis J.A. IOF E.R.P. Osteoporosis in the European Union: A compendium of country-specific reports Arch. Osteoporos. 2013 8 137 10.1007/s11657-013-0137-0 24113838 PMC3880492

3. Manolagas S.C. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr. Rev. 2000 21 115 137 10782361 10.1210/edrv.21.2.0395

4. Sandhu S.K. Hampson G. The pathogenesis, diagnosis, investigation and management of osteoporosis J. Clin. Pathol. 2011 64 1042 1050 10.1136/jcp.2010.077842 21896577

5. Cooper C. Westlake S. Harvey N. Javaid K. Dennison E. Hanson M. Review: Developmental origins of osteoporotic fracture Osteoporos. Int. 2006 17 337 347 10.1007/s00198-005-2039-5 16331359

6. Hui S.L. Slemenda C.W. Johnston C.C. The contribution of bone loss to postmenopausal osteoporosis Osteoporos. Int. 1990 1 30 34 10.1007/BF01880413 2133638

7. Lu J. Shin Y. Yen M.S. Sun S.S. Peak Bone Mass and Patterns of Change in Total Bone Mineral Density and Bone Mineral Contents from Childhood into Young Adulthood J. Clin. Densitometry 2016 19 180 191 10.1016/j.jocd.2014.08.001 PMC4402109 25440183

8. Calvo M.S. Eyre D.R. Gundberg C.M. Molecular basis and clinical application of biological markers of bone turnover Endocr. Rev. 1996 17 333 368 8854049 10.1210/edrv-17-4-333

9. Szulc P. Delmas P.D. Biochemical markers of bone turnover: Potential use in the investigation and management of postmenopausal osteoporosis Osteoporos. Int. 2008 19 1683 1704 10.1007/s00198-008-0660-9 18629570

10. Bauer D.C. Biochemical markers of bone turnover: The Study of Osteoporotic Fracture Bone Markers—Biochemical and Clinical Perspectives Martin Dunitz London, UK 2001 219 223

11. Tromp A.M. Ooms M.E. Popp-Snijders C. Roos J.C. Lips P. Predictors of fractures in elderly women Osteoporos. Int. 2000 11 134 140 10.1007/PL00004174 10793871

12. Akesson K. Ljunghall S. Jonsson B. Sernbo I. Johnell O. Gärdsell P. Obrant K.J. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study of women J. Bone Miner. Res. 1995 10 1823 1829 10.1002/jbmr.5650101127 8592961

13. Garnero P. Hausherr E. Chapuy M.C. Marcelli C. Grandjean H. Muller C. Cormier C. Bréart G. Meunier P.J. Delmas P.D. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study J. Bone Miner. Res. 1996 11 1531 1538 10.1002/jbmr.5650111021 8889854

14. Gerdhem P. Ivaska K.K. Alatalo S.L. Halleen J.M. Hellman J. Isaksson A. Pettersson K. Väänänen H.K. Akesson K. Obrant K.J. Biochemical markers of bone metabolism and prediction of fracture in elderly women J. Bone Miner. Res. 2004 19 386 393 10.1359/JBMR.0301244 15040826

15. Sornay-Rendu E. Munoz F. Garnero P. Duboeuf F. Delmas P.D. Identification of osteopenic women at high risk of fracture: The OFELY study J. Bone Miner. Res. 2005 20 1813 1819 10.1359/JBMR.050609 16160738

16. Tzaphlidou M. Bone architecture: Collagen structure and calcium/phosphorus maps J. Biol. Phys. 2008 34 39 49 10.1007/s10867-008-9115-y 19669491 PMC2577747

17. Greenblatt M.B. Tsai J.N. Wein M.N. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease Clin. Chem. 2017 63 464 474 10.1373/clinchem.2016.259085 27940448 PMC5549920

18. Garnero P. Ferreras M. Karsdal M.A. Nicamhlaoibh R. Risteli J. Borel O. Qvist P. Delmas P.D. Foged N.T. Delaissé J.M. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation J. Bone Miner. Res. 2003 18 859 867 10.1359/jbmr.2003.18.5.859 12733725

19. Takahara K. Kamimura M. Hashidate H. Uchiyama S. Nakagawa H. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures J. Orthop. Sci. 2007 12 219 226 10.1007/s00776-007-1113-6 17530373

20. Vasikaran S. Eastell R. Bruyère O. Foldes A.J. Garnero P. Griesmacher A. McClung M. Morris H.A. Silverman S. Trenti T. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards Osteoporos. Int. 2011 22 391 420 10.1007/s00198-010-1501-1 21184054

21. Bergmann P. Body J.J. Boonen S. Boutsen Y. Devogelaer J.P. Goemaere S. Kaufman J.M. Reginster J.Y. Gangji V. Markers M.A.B.B. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone Club Int. J. Clin. Pract. 2009 63 19 26 10.1111/j.1742-1241.2008.01911.x 19125989 PMC2705815

22. Qvist P. Christgau S. Pedersen B.J. Schlemmer A. Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol and fasting Bone 2002 31 57 61 10.1016/S8756-3282(02)00791-3 12110413

23. Shetty S. Kapoor N. Bondu J.D. Thomas N. Paul T.V. Bone turnover markers: Emerging tool in the management of osteoporosis Indian J. Endocrinol. Metab. 2016 20 846 852 27867890 10.4103/2230-8210.192914 PMC5105571

24. Abe Y. Ishikawa H. Fukao A. Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women Tohoku J. Exp. Med. 2008 214 51 59 10.1620/tjem.214.51 18212487

25. Adler R.A. Osteoporosis: Pathophysiology and Clinical Management 2nd ed. Adler R.A. Humana New York, NY, USA 2010

26. Trull A.K. Biomarkers of Disease: An Evidence-Based Approach Cambridge University Press Cambridge, UK 2002

27. Kraenzlin M.E. Kraenzlin C.A. Meier C. Giunta C. Steinmann B. Automated HPLC assay for urinary collagen cross-links: Effect of age, menopause and metabolic bone diseases Clin. Chem. 2008 54 1546 1553 10.1373/clinchem.2008.105262 18653826

28. Seyedin S.M. Kung V.T. Daniloff Y.N. Hesley R.P. Gomez B. Nielsen L.A. Rosen H.N. Zuk R.F. Immunoassay for urinary pyridinoline: The new marker of bone resorption J. Bone Miner. Res. 1993 8 635 641 10.1002/jbmr.5650080515 8511991

29. Del Campo M.T. González-Casaus M.L. Aguado P. Bernad M. Carrera F. Martínez M.E. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion Osteoporos. Int. 1999 9 449 454 10.1007/s001980050170 10550465

30. Tang J.C. Dutton J.J. Piec I. Green D. Fisher E. Washbourne C.J. Fraser W.D. LC–MS/MS application for urine free pyridinoline and free deoxypyridinoline: Urine markers of collagen and bone degradation Clin. Mass Spectrom. 2016 1 11 18 10.1016/j.clinms.2016.08.001 PMC11322722 39193423

31. Seibel M.J. Biochemical markers of bone turnover: Part I: Biochemistry and variability Clin. Biochem. Rev. 2005 26 97 122 16648882 PMC1320175

32. Lowry M. Hall D.E. Brosnan J.T. Hydroxyproline metabolism by the rat kidney: Distribution of renal enzymes of hydroxyproline catabolism and renal conversion of hydroxyproline to glycine and serine Metabolism 1985 34 955 961 10.1016/0026-0495(85)90145-3 3930916

33. Inoue H. Date Y. Kohashi K. Yoshitomi H. Tsuruta Y. Determination of total hydroxyproline and proline in human serum and urine by HPLC with fluorescence detection Biol. Pharm. Bull. 1996 19 163 166 10.1248/bpb.19.163 8850299

34. Kivirikko K.I. Urinary excretion of hydroxyproline in health and disease Int. Rev. Connect. Tissue Res. 1970 5 93 163 5533228 10.1016/b978-0-12-363705-5.50008-7

35. Krane S.M. Kantrowitz F.G. Byrne M. Pinnell S.R. Singer F.R. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation J. Clin. Investig. 1977 59 819 827 10.1172/JCI108704 404321 PMC372290

36. Smith R. Collagen and disorders of bone Clin. Sci. 1980 59 215 223 10.1042/cs0590215 7000418

37. Prockop D.J. Kivirikko K.I. Tuderman L. Guzman N.A. The biosynthesis of collagen and its disorders (first of two parts) N. Engl. J. Med. 1979 301 13 23 10.1056/NEJM197907053010104 449904

38. Robins S. Turnover of Collagen and Its Precursors Academic Press New York, NY, USA 1980 Volume 135

39. Delmas P.D. Eastell R. Garnero P. Seibel M.J. Stepan J. Foundation C.S.A.I.O. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation Osteoporos. Int. 2000 11 Suppl. 6 2 17 10.1007/s001980070002 11193237

40. Burtis C.A. Ashwood E.R. Bruns D.E. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics 4th ed. Elsevier Saunders St. Louis, MO, USA 2006

41. Kraenzlin M.E. Seibel M.J. Measurement of biochemical markers of bone resorption Dynamics of Bone and Cartilage Metabolism Elsevier Amsterdam, The Netherlands 2006 541 563

42. Moro L. Modricky C. Stagni N. Vittur F. de Bernard B. High-performance liquid chromatographic analysis of urinary hydroxylysyl glycosides as indicators of collagen turnover Analyst 1984 109 1621 1622 10.1039/an9840901621 6532253

43. Leigh S.D. Ju H.S. Lundgard R. Daniloff G.Y. Liu V. Development of an immunoassay for urinary galactosylhydroxylysine J. Immunol. Methods 1998 220 169 178 10.1016/S0022-1759(98)00159-8 9839938

44. Cunningham L.W. Ford J.D. Segrest J.P. The isolation of identical hydroxylysyl glycosides from hydrolysates of soluble collagen and from human urine J. Biol. Chem. 1967 242 2570 2571 6026249

45. Bettica P. Moro L. Robins S.P. Taylor A.K. Talbot J. Singer F.R. Baylink D.J. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks and hydroxyproline compared Clin. Chem. 1992 38 2313 2318 10.1093/clinchem/38.11.2313 1424129

46. Moro L. Modricky C. Rovis L. de Bernard B. Determination of galactosyl hydroxylysine in urine as a means for the identification of osteoporotic women Bone Miner. 1988 3 271 276 10.1016/0378-5122(88)90030-8 3207948

47. Minkin C. Bone acid phosphatase: Tartrate-Resistant acid phosphatase as a marker of osteoclast function Calcif. Tissue Int. 1982 34 285 290 10.1007/BF02411252 6809291

48. Halleen J.M. Karp M. Viloma S. Laaksonen P. Hellman J. Käkönen S.M. Stepan J.J. Holmes S. Väänänen H. Pettersson K. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies J. Bone Miner. Res. 1999 14 464 469 10.1359/jbmr.1999.14.3.464 10027912

49. Halleen J.M. Alatalo S.L. Suominen H. Cheng S. Janckila A.J. Väänänen H.K. Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption J. Bone Miner. Res. 2000 15 1337 1345 10.1359/jbmr.2000.15.7.1337 10893682

50. Hannon R.A. Clowes J.A. Eagleton A.C. Al Hadari A. Eastell R. Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption Bone 2004 34 187 194 10.1016/j.bone.2003.04.002 14751577

51. Mederle O.A. Balas M. Ioanoviciu S.D. Gurban C.V. Tudor A. Borza C. Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis Clin. Interv. Aging 2018 13 1383 1389 10.2147/CIA.S170111 30122910 PMC6080660

52. Irie S. Hayashida N. Shinkawa T. Taira Y. Sekitani Y. Teraoka S. Hashiguchi K. Yoshida K. Morishita M. Takamura N. Suitability of tartrate-resistant acid phosphatase type 5b as a screening marker for bone mineral density in community-dwelling elderly individuals Tohoku J. Exp. Med. 2011 224 105 110 10.1620/tjem.224.105 21597244

53. Halleen J.M. Tiitinen S.L. Ylipahkala H. Fagerlund K.M. Väänänen H.K. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption Clin. Lab. 2006 52 499 509 17078477

54. Kruger T.E. Miller A.H. Godwin A.K. Wang J. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers Crit. Rev. Oncol. Hematol. 2014 89 330 341 10.1016/j.critrevonc.2013.08.013 24071501 PMC3946954

55. Masi L. Brandi M.L. Robey P.G. Crescioli C. Calvo J.C. Bernabei P. Kerr J.M. Yanagishita M. Biosynthesis of bone sialoprotein by a human osteoclast-like cell line (FLG 29.1) J. Bone Miner. Res. 1995 10 187 196 10.1002/jbmr.5650100204 7754798

56. Fisher L.W. Fedarko N.S. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins Connect. Tissue Res. 2003 44 Suppl. 1 33 40 10.1080/03008200390152061 12952171

57. Loosen S.H. Hoening P. Puethe N. Luedde M. Spehlmann M. Ulmer T.F. Cardenas D.V. Roy S. Tacke F. Trautwein C. Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma Sci. Rep. 2019 9 1489 10.1038/s41598-018-38352-2 30728413 PMC6365503

58. Fassbender W.J. Ruf T. Kaiser H.E. Stracke H. Serum levels of immunoreactive bone sialoprotein in osteoporosis: Positive relations to established biochemical parameters of bone turnover In Vivo 2000 14 619 624 11125546

59. Shaarawy M. Hasan M. Serum bone sialoprotein: A marker of bone resorption in postmenopausal osteoporosis Scand. J. Clin. Lab. Investig. 2001 61 513 521 11763409 10.1080/003655101753218274

60. Brömme D. Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution Biol. Chem. Hoppe Seyler 1995 376 379 384 10.1515/bchm3.1995.376.6.379 7576232

61. Kafienah W. Brömme D. Buttle D.J. Croucher L.J. Hollander A.P. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix Biochem. J. 1998 331 727 732 10.1042/bj3310727 9560298 PMC1219411

62. Goto T. Yamaza T. Tanaka T. Cathepsins in the osteoclast J. Electron Microsc. 2003 52 551 558 10.1093/jmicro/52.6.551 14756243

63. Parikka V. Lehenkari P. Sassi M.L. Halleen J. Risteli J. Härkönen P. Väänänen H.K. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts Endocrinology 2001 142 5371 5378 10.1210/endo.142.12.8533 11713237

64. Fujisaki K. Tanabe N. Suzuki N. Kawato T. Takeichi O. Tsuzukibashi O. Makimura M. Ito K. Maeno M. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells Life Sci. 2007 80 1311 1318 10.1016/j.lfs.2006.12.037 17306833

65. Meier C. Meinhardt U. Greenfield J.R. De Winter J. Nguyen T.V. Dunstan C.R. Seibel M.J. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget’s disease Clin. Lab. 2006 52 1 10 16506358

66. Park H.J. Son H.J. Sul O.J. Suh J.H. Choi H.S. 4-Phenylbutyric acid protects against lipopolysaccharide-induced bone loss by modulating autophagy in osteoclasts Biochem. Pharmacol. 2018 151 9 17 10.1016/j.bcp.2018.02.019 29458048

67. Roach H.I. Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption Cell Biol. Int. 1994 18 617 628 10.1006/cbir.1994.1088 8075622

68. Neve A. Corrado A. Cantatore F.P. Osteocalcin: Skeletal and extra-skeletal effects J. Cell Physiol. 2013 228 1149 1153 10.1002/jcp.24278 23139068

69. Wolf G. Function of the bone protein osteocalcin: Definitive evidence Nutr. Rev. 1996 54 332 333 10.1111/j.1753-4887.1996.tb03798.x 9063025

70. Ducy P. Desbois C. Boyce B. Pinero G. Story B. Dunstan C. Smith E. Bonadio J. Goldstein S. Gundberg C. Increased bone formation in osteocalcin-deficient mice Nature 1996 382 448 452 10.1038/382448a0 8684484

71. Tsao Y.T. Huang Y.J. Wu H.H. Liu Y.A. Liu Y.S. Lee O.K. Osteocalcin Mediates Biomineralization during Osteogenic Maturation in Human Mesenchymal Stromal Cells Int. J. Mol. Sci. 2017 18 159 10.3390/ijms18010159 PMC5297792 28106724

72. Delmas P.D. Malaval L. Arlot M.E. Meunier P.J. Serum bone Gla-protein compared to bone histomorphometry in endocrine diseases Bone 1985 6 339 341 10.1016/8756-3282(85)90326-6 3879453

73. Kuo T.R. Chen C.H. Bone biomarker for the clinical assessment of osteoporosis: Recent developments and future perspectives Biomark. Res. 2017 5 18 10.1186/s40364-017-0097-4 28529755 PMC5436437

74. Díaz Diego E.M. Guerrero R. de la Piedra C. Six osteocalcin assays compared Clin. Chem. 1994 40 2071 2077 10.1093/clinchem/40.11.2071 7955381

75. Käkönen S.M. Hellman J. Karp M. Laaksonen P. Obrant K.J. Väänänen H.K. Lövgren T. Pettersson K. Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum Clin. Chem. 2000 46 332 337 10.1093/clinchem/46.3.332 10702519

76. Eick G.N. Madimenos F.C. Cepon-Robins T.J. Devlin M.J. Kowal P. Sugiyama L.S. Snodgrass J.J. Validation of an enzyme-linked immunoassay assay for osteocalcin, a marker of bone formation, in dried blood spots Am. J. Hum. Biol. 2020 e23394 10.1002/ajhb.23394 32017301

77. Stigbrand T. Present status and future trends of human alkaline phosphatases Prog. Clin. Biol. Res. 1984 166 3 14 6504935

78. Magnusson P. Larsson L. Magnusson M. Davie M.W. Sharp C.A. Isoforms of bone alkaline phosphatase: Characterization and origin in human trabecular and cortical bone J. Bone Miner. Res. 1999 14 1926 1933 10.1359/jbmr.1999.14.11.1926 10571693

79. Harris H. The human alkaline phosphatases: What we know and what we don’t know Clin. Chim. Acta 1990 186 133 150 10.1016/0009-8981(90)90031-M 2178806

80. Hlaing T.T. Compston J.E. Biochemical markers of bone turnover-uses and limitations Ann. Clin. Biochem. 2014 51 189 202 10.1177/0004563213515190 24399365

81. Gomez B. Ardakani S. Ju J. Jenkins D. Cerelli M.J. Daniloff G.Y. Kung V.T. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum Clin. Chem. 1995 41 1560 1566 10.1093/clinchem/41.11.1560 7586543

82. Orwoll E.S. Bliziotes M. Osteoporosis: Pathophysiology and Clinical Management Humana Press Totowa, NJ, USA 2003

83. Koivula M.K. Risteli L. Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum Clin. Biochem. 2012 45 920 927 10.1016/j.clinbiochem.2012.03.023 22480789

84. Melkko J. Hellevik T. Risteli L. Risteli J. Smedsrød B. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells J. Exp. Med. 1994 179 405 412 10.1084/jem.179.2.405 8294857 PMC2191385

85. Krege J.H. Lane N.E. Harris J.M. Miller P.D. PINP as a biological response marker during teriparatide treatment for osteoporosis Osteoporos. Int. 2014 25 2159 2171 10.1007/s00198-014-2646-0 24599274 PMC4134485

86. Bentsen K.D. Henriksen J.H. Boesby S. Hørslev-Petersen K. Lorenzen I. Hepatic and renal extraction of circulating type III procollagen amino-terminal propeptide and hyaluronan in pig J. Hepatol. 1989 9 177 183 10.1016/0168-8278(89)90048-2 2809157

87. Chen P. Satterwhite J.H. Licata A.A. Lewiecki E.M. Sipos A.A. Misurski D.M. Wagman R.B. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J. Bone Miner. Res. 2005 20 962 970 10.1359/JBMR.050105 15883636

88. Vasikaran S.D. Chubb S.P. Ebeling P.R. Jenkins N. Jones G.R. Kotowicz M.A. Morris H.A. Schneider H.G. Seibel M.J. Ward G. Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults Clin. Biochem. Rev. 2014 35 237 242 25678728 PMC4310062

89. Smedsrød B. Melkko J. Risteli L. Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells Biochem. J. 1990 271 345 350 10.1042/bj2710345 2241919 PMC1149560

90. Vasikaran S. Cooper C. Eastell R. Griesmacher A. Morris H.A. Trenti T. Kanis J.A. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis Clin. Chem. Lab. Med. 2011 49 1271 1274 10.1515/CCLM.2011.602 21605012

91. Bauer D. Krege J. Lane N. Leary E. Libanati C. Miller P. Myers G. Silverman S. Vesper H.W. Lee D. National Bone Health Alliance Bone Turnover Marker Project: Current practices and the need for US harmonization, standardization and common reference ranges Osteoporos. Int. 2012 23 2425 2433 10.1007/s00198-012-2049-z 22797491 PMC4011662

92. Li W.C. Chen Y.C. Yang R.S. Tsauo J.Y. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: A systematic review and meta-analysis Clin. Rehabil. 2009 23 888 896 10.1177/0269215509339002 19717503

93. Lambert C. Beck B.R. Watson S.L. Harding A.T. Weeks B.K. Enjoyment and acceptability of different exercise modalities to improve bone health in young adult women Health Promot. J. Aust. 2020 10.1002/hpja.321 31943497

94. Bragonzoni L. Barone G. Benvenuti F. Canal V. Ripamonti C. Marini S. Dallolio L. A Randomized Clinical Trial to Evaluate the Efficacy and Safety of the ACTLIFE Exercise Program for Women with Post-menopausal Osteoporosis: Study Protocol Int. J. Environ. Res. Public Health 2020 17 809 10.3390/ijerph17030809 PMC7036985 32012966

95. Filipović T. Gopčević K. Dimitrijević S. Hrković M. Backović A. Lazović M. Effects of 12-Week Exercise Program on Enzyme Activity of Serum Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Female Patients with Postmenopausal Osteoporosis: A Randomized Control Study BioMed Res. Int. 2020 2020 9758289 10.1155/2020/9758289 32071923 PMC7011433

96. Bailey R.L. Zou P. Wallace T.C. McCabe G.P. Craig B.A. Jun S. Cauley J.A. Weaver C.M. Calcium Supplement Use Is Associated With Less Bone Mineral Density Loss but Does Not Lessen the Risk of Bone Fracture Across the Menopause Transition: Data From the Study of Women’s Health Across the Nation JBMR Plus 2020 4 e10246 10.1002/jbm4.10246 31956850 PMC6957983

97. Weaver C.M. Alexander D.D. Boushey C.J. Dawson-Hughes B. Lappe J.M. LeBoff M.S. Liu S. Looker A.C. Wallace T.C. Wang D.D. Calcium plus vitamin D supplementation and risk of fractures: An updated meta-analysis from the National Osteoporosis Foundation Osteoporos. Int. 2016 27 367 376 10.1007/s00198-015-3386-5 26510847 PMC4715837

98. Riggs B.L. Khosla S. Melton L.J. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men J. Bone Miner. Res. 1998 13 763 773 10.1359/jbmr.1998.13.5.763 9610739

99. Morito K. Hirose T. Kinjo J. Hirakawa T. Okawa M. Nohara T. Ogawa S. Inoue S. Muramatsu M. Masamune Y. Interaction of phytoestrogens with estrogen receptors α and β Biol. Pharm. Bull. 2001 24 351 356 10.1248/bpb.24.351 11305594

100. Lambert M.N.T. Thybo C.B. Lykkeboe S. Rasmussen L.M. Frette X. Christensen L.P. Jeppesen P.B. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: A randomized controlled trial Am. J. Clin. Nutr. 2017 106 909 920 10.3945/ajcn.117.153353 28768651

101. Liu J. Ho S.C. Su Y.X. Chen W.Q. Zhang C.X. Chen Y.M. Effect of long-term intervention of soy isoflavones on bone mineral density in women: A meta-analysis of randomized controlled trials Bone 2009 44 948 953 10.1016/j.bone.2008.12.020 19168161

102. De Martinis M. Sirufo M.M. Ginaldi L. Osteoporosis: Current and emerging therapies targeted to immunological checkpoints Curr. Med. Chem. 2019 26 1 16 10.2174/0929867326666190730113123 31362684 PMC8206194

103. Cheng C. Wentworth K. Shoback D.M. New Frontiers in Osteoporosis Therapy Annu. Rev. Med. 2019 71 277 288 10.1146/annurev-med-052218-020620 31509477

104. Rossouw J.E. Anderson G.L. Prentice R.L. LaCroix A.Z. Kooperberg C. Stefanick M.L. Jackson R.D. Beresford S.A. Howard B.V. Johnson K.C. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial JAMA 2002 288 321 333 12117397 10.1001/jama.288.3.321

105. Nelson E.R. Wardell S.E. McDonnell D.P. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis Bone 2013 53 42 50 10.1016/j.bone.2012.11.011 23168292 PMC3552054

106. An K.C. Selective Estrogen Receptor Modulators Asian Spine J. 2016 10 787 791 10.4184/asj.2016.10.4.787 27559463 PMC4995266

107. Martinkovich S. Shah D. Planey S.L. Arnott J.A. Selective estrogen receptor modulators: Tissue specificity and clinical utility Clin. Interv. Aging 2014 9 1437 1452 25210448 10.2147/CIA.S66690 PMC4154886

108. Stapleton M. Sawamoto K. Alméciga-Díaz C.J. Mackenzie W.G. Mason R.W. Orii T. Tomatsu S. Development of Bone Targeting Drugs Int. J. Mol. Sci. 2017 18 1345 10.3390/ijms18071345 PMC5535838 28644392

109. Reszka A.A. Rodan G.A. Bisphosphonate mechanism of action Curr. Rheumatol. Rep. 2003 5 65 74 10.1007/s11926-003-0085-6 12590887

110. Eriksen E.F. Díez-Pérez A. Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review Bone 2014 58 126 135 10.1016/j.bone.2013.09.023 24120384

111. Kennel K.A. Drake M.T. Adverse effects of bisphosphonates: Implications for osteoporosis management Mayo Clin. Proc. 2009 84 632 637 10.1016/S0025-6196(11)60752-0 19567717 PMC2704135

112. Zaheer S. LeBoff M. Lewiecki E.M. Denosumab for the treatment of osteoporosis Expert Opin. Drug Metab. Toxicol. 2015 11 461 470 10.1517/17425255.2015.1000860 25614274 PMC4480604

113. Baron R. Ferrari S. Russell R.G. Denosumab and bisphosphonates: Different mechanisms of action and effects Bone 2011 48 677 692 10.1016/j.bone.2010.11.020 21145999

114. Anastasilakis A.D. Polyzos S.A. Makras P. Therapy of endocrine disease: Denosumab vs. bisphosphonates for the treatment of postmenopausal osteoporosis Eur. J. Endocrinol. 2018 179 R31 R45 10.1530/EJE-18-0056 29691303

115. Hodsman A.B. Bauer D.C. Dempster D.W. Dian L. Hanley D.A. Harris S.T. Kendler D.L. McClung M.R. Miller P.D. Olszynski W.P. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use Endocr. Rev. 2005 26 688 703 10.1210/er.2004-0006 15769903

116. Lindsay R. Krege J.H. Marin F. Jin L. Stepan J.J. Teriparatide for osteoporosis: Importance of the full course Osteoporos. Int. 2016 27 2395 2410 10.1007/s00198-016-3534-6 26902094 PMC4947115

117. Neer R.M. Arnaud C.D. Zanchetta J.R. Prince R. Gaich G.A. Reginster J.Y. Hodsman A.B. Eriksen E.F. Ish-Shalom S. Genant H.K. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 2001 344 1434 1441 10.1056/NEJM200105103441904 11346808

118. Vahle J.L. Sato M. Long G.G. Young J.K. Francis P.C. Engelhardt J.A. Westmore M.S. Linda Y. Nold J.B. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety Toxicol. Pathol. 2002 30 312 321 10.1080/01926230252929882 12051548

119. Vahle J.L. Long G.G. Sandusky G. Westmore M. Ma Y.L. Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose Toxicol. Pathol. 2004 32 426 438 10.1080/01926230490462138 15204966

120. Schemitsch E.H. Miclau T. Karachalios T. Nowak L.L. Sancheti P. Poolman R.W. Caminis J. Daizadeh N. Dent-Acosta R.E. Egbuna O. A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures JBJS 2020 10.2106/JBJS.19.00790 PMC7508283 31977817

121. Ke H.Z. Richards W.G. Li X. Ominsky M.S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases Endocr. Rev. 2012 33 747 783 10.1210/er.2011-1060 22723594

122. Lewiecki E.M. New targets for intervention in the treatment of postmenopausal osteoporosis Nat. Rev. Rheumatol. 2011 7 631 638 10.1038/nrrheum.2011.130 21931340

123. Lewiecki E.M. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases Ther. Adv. Musculoskelet. Dis. 2014 6 48 57 10.1177/1759720X13510479 24688605 PMC3956136

124. Dominici M. Le Blanc K. Mueller I. Slaper-Cortenbach I. Marini F. Krause D. Deans R. Keating A. Prockop D. Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606

125. James A.W. Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation Scientifica 2013 2013 684736 10.1155/2013/684736 24416618 PMC3874981

126. Giampietro P.F. McCarty C. Mukesh B. McKiernan F. Wilson D. Shuldiner A. Liu J. LeVasseur J. Ivacic L. Kitchner T. The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: A pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort Osteoporos. Int. 2010 21 467 477 10.1007/s00198-009-0981-3 19506792

127. Infante A. Rodríguez C.I. Osteogenesis and aging: Lessons from mesenchymal stem cells Stem Cell Res. Ther. 2018 9 1 7 10.1186/s13287-018-0995-x 30257716 PMC6158877

128. Duque G. Bone and fat connection in aging bone Curr. Opin. Rheumatol. 2008 20 429 434 10.1097/BOR.0b013e3283025e9c 18525356

129. Rodríguez J.P. Garat S. Gajardo H. Pino A.M. Seitz G. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics J. Cell Biochem. 1999 75 414 423 10.1002/(SICI)1097-4644(19991201)75:3<414::AID-JCB7>3.0.CO;2-C 10536365

130. Rodríguez J.P. Montecinos L. Ríos S. Reyes P. Martínez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation J. Cell Biochem. 2000 79 557 565 10.1002/1097-4644(20001215)79:4<557::AID-JCB40>3.0.CO;2-H 10996846

131. Chen Q. Shou P. Zheng C. Jiang M. Cao G. Yang Q. Cao J. Xie N. Velletri T. Zhang X. Fate decision of mesenchymal stem cells: Adipocytes or osteoblasts? Cell Death Differ. 2016 23 1128 1139 10.1038/cdd.2015.168 26868907 PMC4946886

132. Marie P.J. Transcription factors controlling osteoblastogenesis Arch. Biochem. Biophys. 2008 473 98 105 10.1016/j.abb.2008.02.030 18331818

133. Cheng Y.H. Dong J.C. Bian Q. Small molecules for mesenchymal stem cell fate determination World J. Stem Cells 2019 11 1084 10.4252/wjsc.v11.i12.1084 31875870 PMC6904864

134. Almalki S.G. Agrawal D.K. Key transcription factors in the differentiation of mesenchymal stem cells Differentiation 2016 92 41 51 10.1016/j.diff.2016.02.005 27012163 PMC5010472

135. Valenti M.T. Garbin U. Pasini A. Zanatta M. Stranieri C. Manfro S. Zucal C. Dalle Carbonare L. Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPARγ2 expression in MSCs-like of osteoporotic patients PLoS ONE 2011 6 e20363 10.1371/journal.pone.0020363 21674037 PMC3108593

136. Li Y. Jin D. Xie W. Wen L. Chen W. Xu J. Ding J. Ren D. PPAR-γ and Wnt Regulate the Differentiation of MSCs into Adipocytes and Osteoblasts Respectively Curr. Stem Cell Res. Ther. 2018 13 185 192 10.2174/1574888X12666171012141908 29034841

137. Cao J.J. Effects of obesity on bone metabolism J. Orthop. Surg. Res. 2011 6 30 10.1186/1749-799X-6-30 21676245 PMC3141563

138. Marie P.J. Kassem M. Osteoblasts in osteoporosis: Past, emerging and future anabolic targets Eur. J. Endocrinol. 2011 165 1 10 10.1530/EJE-11-0132 21543379

139. Benisch P. Schilling T. Klein-Hitpass L. Frey S.P. Seefried L. Raaijmakers N. Krug M. Regensburger M. Zeck S. Schinke T. The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors PLoS ONE 2012 7 e45142 10.1371/journal.pone.0045142 23028809 PMC3454401

140. von Bahr L. Batsis I. Moll G. Hägg M. Szakos A. Sundberg B. Uzunel M. Ringden O. Le Blanc K. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation Stem Cells 2012 30 1575 1578 10.1002/stem.1118 22553154

141. Lee K. Kim H. Kim J.M. Kim J.R. Kim K.J. Kim Y.J. Park S.I. Jeong J.H. Moon Y.M. Lim H.S. Systemic transplantation of human adipose-derived stem cells stimulates bone repair by promoting osteoblast and osteoclast function J. Cell Mol. Med. 2011 15 2082 2094 10.1111/j.1582-4934.2010.01230.x 21159123 PMC4394219

142. Sinder B.P. Novak S. Wee N.K.Y. Basile M. Maye P. Matthews B.G. Kalajzic I. Engraftment of skeletal progenitor cells by bone directed transplantation improves osteogenesis imperfecta murine bone phenotype Stem Cells 2019 1 12 10.1002/stem.3133 PMC7755312 31859429

143. Hu L. Yin C. Zhao F. Ali A. Ma J. Qian A. Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment Int. J. Mol. Sci. 2018 19 360 10.3390/ijms19020360 PMC5855582 29370110

144. Ichioka N. Inaba M. Kushida T. Esumi T. Takahara K. Inaba K. Ogawa R. Iida H. Ikehara S. Prevention of senile osteoporosis in SAMP6 mice by intrabone marrow injection of allogeneic bone marrow cells Stem Cells 2002 20 542 551 10.1634/stemcells.20-6-542 12456962

145. Ocarino N.M. Boeloni J.N. Jorgetti V. Gomes D.A. Goes A.M. Serakides R. Intra-bone marrow injection of mesenchymal stem cells improves the femur bone mass of osteoporotic female rats Connect. Tissue Res. 2010 51 426 433 10.3109/03008201003597049 20373890

146. Sui B. Hu C. Zhang X. Zhao P. He T. Zhou C. Qiu X. Chen N. Zhao X. Jin Y. Allogeneic Mesenchymal Stem Cell Therapy Promotes Osteoblastogenesis and Prevents Glucocorticoid-Induced Osteoporosis Stem Cells Transl. Med. 2016 5 1238 1246 10.5966/sctm.2015-0347 27365487 PMC4996443

147. Kiernan J. Hu S. Grynpas M.D. Davies J.E. Stanford W.L. Systemic Mesenchymal Stromal Cell Transplantation Prevents Functional Bone Loss in a Mouse Model of Age-Related Osteoporosis Stem Cells Transl. Med. 2016 5 683 693 10.5966/sctm.2015-0231 26987353 PMC4835247

148. Cao L. Liu G. Gan Y. Fan Q. Yang F. Zhang X. Tang T. Dai K. The use of autologous enriched bone marrow MSCs to enhance osteoporotic bone defect repair in long-term estrogen deficient goats Biomaterials 2012 33 5076 5084 10.1016/j.biomaterials.2012.03.069 22504017

149. Stolzing A. Jones E. McGonagle D. Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies Mech. Ageing Dev. 2008 129 163 173 10.1016/j.mad.2007.12.002 18241911

150. Kern S. Eichler H. Stoeve J. Klüter H. Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood or adipose tissue Stem Cells 2006 24 1294 1301 10.1634/stemcells.2005-0342 16410387

151. Jurgens W.J. Oedayrajsingh-Varma M.J. Helder M.N. Zandiehdoulabi B. Schouten T.E. Kuik D.J. Ritt M.J. van Milligen F.J. Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: Implications for cell-based therapies Cell Tissue Res. 2008 332 415 426 10.1007/s00441-007-0555-7 18379826 PMC2386754

152. Choudhery M.S. Badowski M. Muise A. Pierce J. Harris D.T. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation J. Transl. Med. 2014 12 8 10.1186/1479-5876-12-8 24397850 PMC3895760

153. Mirsaidi A. Genelin K. Vetsch J.R. Stanger S. Theiss F. Lindtner R.A. von Rechenberg B. Blauth M. Müller R. Kuhn G.A. Therapeutic potential of adipose-derived stromal cells in age-related osteoporosis Biomaterials 2014 35 7326 7335 10.1016/j.biomaterials.2014.05.016 24933514

154. Cho S.W. Sun H.J. Yang J.Y. Jung J.Y. Choi H.J. An J.H. Kim S.W. Kim S.Y. Park K.J. Shin C.S. Human adipose tissue-derived stromal cell therapy prevents bone loss in ovariectomized nude mouse Tissue Eng. Part A 2012 18 1067 1078 10.1089/ten.tea.2011.0355 22220675

155. Ye X. Zhang P. Xue S. Xu Y. Tan J. Liu G. Adipose-derived stem cells alleviate osteoporosis by enhancing osteogenesis and inhibiting adipogenesis in a rabbit model Cytotherapy 2014 16 1643 1655 10.1016/j.jcyt.2014.07.009 25231892

156. Bieback K. Brinkmann I. Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy World J. Stem Cells 2010 2 81 92 21607124 10.4252/wjsc.v2.i4.81 PMC3097927

157. Ilic D. Miere C. Lazic E. Umbilical cord blood stem cells: Clinical trials in non-hematological disorders Br. Med. Bull. 2012 102 43 57 10.1093/bmb/lds008 22544780

158. Karahuseyinoglu S. Cinar O. Kilic E. Kara F. Akay G.G. Demiralp D.O. Tukun A. Uckan D. Can A. Biology of stem cells in human umbilical cord stroma: In situ and in vitro surveys Stem Cells 2007 25 319 331 10.1634/stemcells.2006-0286 17053211

159. Diao Y. Ma Q. Cui F. Zhong Y. Human umbilical cord mesenchymal stem cells: Osteogenesis in vivo as seed cells for bone tissue engineering J. BioMed Mater. Res. A 2009 91 123 131 10.1002/jbm.a.32186 18767055

160. An J.H. Park H. Song J.A. Ki K.H. Yang J.Y. Choi H.J. Cho S.W. Kim S.W. Kim S.Y. Yoo J.J. Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice Tissue Eng. Part A 2013 19 685 696 10.1089/ten.tea.2012.0047 23215868 PMC3568969

161. Pacifici R. Brown C. Puscheck E. Friedrich E. Slatopolsky E. Maggio D. McCracken R. Avioli L.V. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells Proc. Natl. Acad. Sci. USA 1991 88 5134 5138 10.1073/pnas.88.12.5134 2052592 PMC51826

162. Braun T. Schett G. Pathways for bone loss in inflammatory disease Curr. Osteoporos. Rep. 2012 10 101 108 10.1007/s11914-012-0104-5 22527726

163. Barbour K.E. Boudreau R. Danielson M.E. Youk A.O. Wactawski-Wende J. Greep N.C. LaCroix A.Z. Jackson R.D. Wallace R.B. Bauer D.C. Inflammatory markers and the risk of hip fracture: The Women’s Health Initiative J. Bone Miner. Res. 2012 27 1167 1176 10.1002/jbmr.1559 22392817 PMC3361578

164. Hughes D.E. Dai A. Tiffee J.C. Li H.H. Mundy G.R. Boyce B.F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta Nat. Med. 1996 2 1132 1136 10.1038/nm1096-1132 8837613

165. Piva R. Penolazzi L. Lambertini E. Giordano S. Gambari R. Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha Apoptosis 2005 10 1079 1094 10.1007/s10495-005-0618-8 16151641

166. Srivastava S. Toraldo G. Weitzmann M.N. Cenci S. Ross F.P. Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation J. Biol. Chem. 2001 276 8836 8840 10.1074/jbc.M010764200 11121427

167. Manolagas S.C. O’Brien C.A. Almeida M. The role of estrogen and androgen receptors in bone health and disease Nat. Rev. Endocrinol. 2013 9 699 712 10.1038/nrendo.2013.179 24042328 PMC3971652

168. Eghbali-Fatourechi G. Khosla S. Sanyal A. Boyle W.J. Lacey D.L. Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J. Clin. Investig. 2003 111 1221 1230 10.1172/JCI200317215 12697741 PMC152939

169. D’Amelio P. Grimaldi A. Di Bella S. Brianza S.Z.M. Cristofaro M.A. Tamone C. Giribaldi G. Ulliers D. Pescarmona G.P. Isaia G. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: A key mechanism in osteoporosis Bone 2008 43 92 100 10.1016/j.bone.2008.02.017 18407820

170. Adeel S. Singh K. Vydareny K.H. Kumari M. Shah E. Weitzmann M.N. Tangpricha V. Bone loss in surgically ovariectomized premenopausal women is associated with T lymphocyte activation and thymic hypertrophy J. Investig. Med. 2013 61 1178 1183 10.2310/JIM.0000000000000016 24141238 PMC3918442

171. Masuzawa T. Miyaura C. Onoe Y. Kusano K. Ohta H. Nozawa S. Suda T. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow J. Clin. Investig. 1994 94 1090 1097 10.1172/JCI117424 8083350 PMC295170

172. El-Jawhari J.J. Jones E. Giannoudis P.V. The roles of immune cells in bone healing; what we know, do not know and future perspectives Injury 2016 47 2399 2406 10.1016/j.injury.2016.10.008 27809990

173. Richardson J. Hill A.M. Johnston C.J. McGregor A. Norrish A.R. Eastwood D. Lavy C.B. Fracture healing in HIV-positive populations J. Bone Jt. Surg. Br. 2008 90 988 994 10.1302/0301-620X.90B8.20861 18669951

174. Askalonov A.A. Changes in some indices of cellular immunity in patients with uncomplicated and complicated healing of bone fractures J. Hyg. Epidemiol. Microbiol. Immunol. 1981 25 307 310 7299112

175. Nam D. Mau E. Wang Y. Wright D. Silkstone D. Whetstone H. Whyne C. Alman B. T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair PLoS ONE 2012 7 e40044 10.1371/journal.pone.0040044 22768215 PMC3386936

176. Medhat D. Rodríguez C.I. Infante A. Immunomodulatory Effects of MSCs in Bone Healing Int. J. Mol. Sci. 2019 20 5467 10.3390/ijms20215467 PMC6862454 31684035

177. Wang Y. Chen X. Cao W. Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications Nat. Immunol. 2014 15 1009 1016 10.1038/ni.3002 25329189

178. Kean T.J. Lin P. Caplan A.I. Dennis J.E. MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies and Immune Modulation Stem Cells Int. 2013 2013 732742 10.1155/2013/732742 24000286 PMC3755386

179. Aggarwal S. Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses Blood 2005 105 1815 1822 10.1182/blood-2004-04-1559 15494428

180. Chinnadurai R. Copland I.B. Garcia M.A. Petersen C.T. Lewis C.N. Waller E.K. Kirk A.D. Galipeau J. Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing Stem Cells 2016 34 2429 2442 10.1002/stem.2415 27299362 PMC5016228

181. Corcione A. Benvenuto F. Ferretti E. Giunti D. Cappiello V. Cazzanti F. Risso M. Gualandi F. Mancardi G.L. Pistoia V. Human mesenchymal stem cells modulate B-cell functions Blood 2006 107 367 372 10.1182/blood-2005-07-2657 16141348

182. Tabera S. Pérez-Simón J.A. Díez-Campelo M. Sánchez-Abarca L.I. Blanco B. López A. Benito A. Ocio E. Sánchez-Guijo F.M. Cañizo C. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes Haematologica 2008 93 1301 1309 10.3324/haematol.12857 18641017

183. Rosado M.M. Bernardo M.E. Scarsella M. Conforti A. Giorda E. Biagini S. Cascioli S. Rossi F. Guzzo I. Vivarelli M. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells Stem Cells Dev. 2015 24 93 103 10.1089/scd.2014.0155 25036865 PMC4273193

184. Jiang X.X. Zhang Y. Liu B. Zhang S.X. Wu Y. Yu X.D. Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells Blood 2005 105 4120 4126 10.1182/blood-2004-02-0586 15692068

185. Beyth S. Borovsky Z. Mevorach D. Liebergall M. Gazit Z. Aslan H. Galun E. Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness Blood 2005 105 2214 2219 10.1182/blood-2004-07-2921 15514012

186. Nauta A.J. Westerhuis G. Kruisselbrink A.B. Lurvink E.G. Willemze R. Fibbe W.E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting Blood 2006 108 2114 2120 10.1182/blood-2005-11-011650 16690970 PMC1895546

187. Spaggiari G.M. Capobianco A. Becchetti S. Mingari M.C. Moretta L. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation Blood 2006 107 1484 1490 10.1182/blood-2005-07-2775 16239427

188. Yuan X. Qin X. Wang D. Zhang Z. Tang X. Gao X. Chen W. Sun L. Mesenchymal stem cell therapy induces FLT3L and CD1c Nat. Commun. 2019 10 2498 10.1038/s41467-019-10491-8 31175312 PMC6555800

189. Spaggiari G.M. Capobianco A. Abdelrazik H. Becchetti F. Mingari M.C. Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2 Blood 2008 111 1327 1333 10.1182/blood-2007-02-074997 17951526

190. Thomas H. Jäger M. Mauel K. Brandau S. Lask S. Flohé S.B. Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion Mediat. Inflamm. 2014 2014 143463 10.1155/2014/143463 24876666 PMC4021755

191. Raffaghello L. Bianchi G. Bertolotto M. Montecucco F. Busca A. Dallegri F. Ottonello L. Pistoia V. Human mesenchymal stem cells inhibit neutrophil apoptosis: A model for neutrophil preservation in the bone marrow niche Stem Cells 2008 26 151 162 10.1634/stemcells.2007-0416 17932421

192. Brandau S. Jakob M. Hemeda H. Bruderek K. Janeschik S. Bootz F. Lang S. Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge J. Leukoc. Biol. 2010 88 1005 1015 10.1189/jlb.0410207 20682625

193. Hall S.R. Tsoyi K. Ith B. Padera R.F. Lederer J.A. Wang Z. Liu X. Perrella M.A. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: The importance of neutrophils Stem Cells 2013 31 397 407 10.1002/stem.1270 23132816 PMC3572335

194. Joel M.D.M. Yuan J. Wang J. Yan Y. Qian H. Zhang X. Xu W. Mao F. MSC: Immunoregulatory effects, roles on neutrophils and evolving clinical potentials Am. J. Transl. Res. 2019 11 3890 3904 31312397 PMC6614638

195. Prockop D.J. Concise review: Two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation Stem Cells 2013 31 2042 2046 10.1002/stem.1400 23681848

196. Vasandan A.B. Jahnavi S. Shashank C. Prasad P. Kumar A. Prasanna S.J. Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE Sci. Rep. 2016 6 38308 10.1038/srep38308 27910911 PMC5133610

197. Zhang Q.Z. Su W.R. Shi S.H. Wilder-Smith P. Xiang A.P. Wong A. Nguyen A.L. Kwon C.W. Le A.D. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing Stem Cells 2010 28 1856 1868 10.1002/stem.503 20734355 PMC3114043

198. Cho D.I. Kim M.R. Jeong H.Y. Jeong H.C. Jeong M.H. Yoon S.H. Kim Y.S. Ahn Y. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages Exp. Mol. Med. 2014 46 e70 10.1038/emm.2013.135 24406319 PMC3909888

199. Choi H. Lee R.H. Bazhanov N. Oh J.Y. Prockop D.J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages Blood 2011 118 330 338 10.1182/blood-2010-12-327353 21551236 PMC3138686

200. Bernardo M.E. Fibbe W.E. Mesenchymal stromal cells: Sensors and switchers of inflammation Cell Stem Cell 2013 13 392 402 10.1016/j.stem.2013.09.006 24094322

201. Ilich J.Z. Kelly O.J. Kim Y. Spicer M.T. Low-grade chronic inflammation perpetuated by modern diet as a promoter of obesity and osteoporosis Arch. Hyg. Rada Toksikol. 2014 65 139 148 10.2478/10004-1254-65-2014-2541 24945416